Thymopentin and infections in a peritoneal dialysis cohort
Observational study · 2025
- What was studied
- 100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.
- Main finding
- Infection episodes · 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).
Reported findings and study design
Reported findings
Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.
Population or model 100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.
Dose, route and schedule
Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.
Protocol source ↗ · Original full text, including the infection and safety tables.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Infection episodes | 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034). | |
| Peritonitis episodes | 1 versus 8 (p=0.031). | |
| Severe infection and mortality | 5 versus 10 severe infections (p=0.161). One patient died in each group. | |
| IL-6 at week 12 | The full results show a smaller median increase (0.20 versus 1.10 pg/mL, p=0.036). There was no significant difference at weeks 24 or 48. | |
| Cell counts and adverse-event reporting | No significant differences in CD4 counts or the CD4:CD8 ratio. The authors reported 12 versus 24 adverse events. |
Reported events during 48 weeks
| Measure | Thymopentin (n=50) | Control (n=50) |
|---|---|---|
| Infection episodes | 36 | 49 |
| Infection episodes per person-year | 0.73 | 1.00 |
| Peritonitis episodes | 1 | 8 |
| Severe infection | 5 | 10 |
| Deaths | 1 | 1 |
| Reported adverse events | 12 | 24 |
Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.
Source details
Original full text, including the infection and safety tables.
Sources checked
Added to the library
Citation
X. Chen, Y. Ruan, J. Xie, X. Huang, C. Zhang, Y. Cui, T. Xu, H. Ren. Thymopentin and infections in a peritoneal dialysis cohort BMC Nephrology 26, article 538
Study source ↗ · DOI 10.1186/s12882-025-04465-w · Bibliography entry · Link to this summary